|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6623 - 0.6875|
|52 Week Range||0.4600 - 0.8400|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
VANCOUVER, Washington, March 14, 2018-- CytoDyn Inc., a biotechnology company developing new antibody therapies for combating human immunodeficiency virus infection, announces that the Independent Data ...
NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...
VANCOUVER, Washington, Feb. 20, 2018-- CytoDyn Inc. reports the successful achievement of the primary endpoint in its CD02 Phase 2 b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral ...
NEW YORK, April 3, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...